Sanofi India Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Sanofi India Ltd filed with BSE on 10 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Sanofi India reported quarter two 2026 results with diabetes business growth of close to 14%, driven by Toujeo and Soliqua, while the partnership business with Emcure and Cipla grew 2% in the quarter. Profit before tax and exceptional items rose 19% year-on-year to INR 112 crores from INR 94 crores, with margin improving to 27% of net sales from 24%. Management discussed export market challenges in Australia offset partly by other markets, and noted cash balance grew 34%.
Numbers mentioned
Diabetes business growth: 14% (Q2 2026)
p. 3
“If you look at the quarter two results, closer to 14% double-digit growth, powered by innovative portfolio, which is both Toujeo and Soliqua.”
Deepak Arora, page 3 of the filed PDF · View the filing
Public sector growth contribution to diabetes: 70% (Q2 2026)
p. 3
“And you can see that close to 70% growth is attributed by that discipline of execution, expansion, and acceleration in public sector”
Deepak Arora, page 3 of the filed PDF · View the filing
Partnership business growth: 2% (Q2 2026)
p. 3
“Also happy to share that there is a 2% growth in quarter two over last year's quarter two, based on the continued ROI or Return of Investment which we looked into for partnership with Emcure and Cipla”
Deepak Arora, page 3 of the filed PDF · View the filing
Lantus market share by value: 47%
p. 4
“we still continue to be a market leader, closer to 47% market share by value and volume acceleration of plus 6% with Lantus”
Deepak Arora, page 4 of the filed PDF · View the filing
Toujeo market share growth in value: 11%
p. 4
“Toujeo, being the second preferred second generation basal insulin, has grown by 11% in the market share in value.”
Deepak Arora, page 4 of the filed PDF · View the filing
Basal analog market share by value: 58%
p. 4
“we have 58% value in the market share and close to 61% in the volume”
Deepak Arora, page 4 of the filed PDF · View the filing
Soliqua growth: 16%
p. 4
“Soliqua continues to grow by 16% quarter-by-quarter.”
Deepak Arora, page 4 of the filed PDF · View the filing
CSR beneficiaries by year end: 600,000 plus (2026)
p. 5
“By end of this year, around 600,000 plus direct beneficiaries will be reached with different programs”
Deepak Arora, page 5 of the filed PDF · View the filing
Total income growth: 7% (Q2 2026)
p. 5
“So, as mentioned by Deepak, strong quarter, so we try to detail the total income. So, plus 7%, mainly 94% where we focused on the sales, which is growing by 6% between the domestic and the export.”
Rachid Ayari, page 5 of the filed PDF · View the filing
Sales growth YTD H1: -2% (YTD H1 2026)
p. 5
“if we look to the YTD right now, June 2026, we are at minus 4% offsetting significant gap that we have in Q1, minus 2% on the sales, domestic and export”
Rachid Ayari, page 5 of the filed PDF · View the filing
Domestic sales growth: 8% (Q2 2026)
p. 5
“So if you take the quarter as mentioned by Deepak, plus 8% for the domestic, minus 2% in the in the export part”
Rachid Ayari, page 5 of the filed PDF · View the filing
Diabetes growth H1: 17% (YTD H1 2026)
p. 5
“with good performance from diabetes, so double-digit growth, plus 17%.”
Rachid Ayari, page 5 of the filed PDF · View the filing
Operating expenses change YTD H1: -15% (YTD H1 2026)
p. 6
“So, if we look for from quarter perspective, it's minus 5%. In YTD H1, minus 15%.”
Rachid Ayari, page 6 of the filed PDF · View the filing
Profit before tax and exceptional items: INR 112 crores, up 19% (Q2 2026)
p. 6
“so strong performance for the quarter with double-digit growth, plus 19%, so from INR 94 crores to INR 112 crores.”
Rachid Ayari, page 6 of the filed PDF · View the filing
Profit before tax margin: 27% (Q2 2026)
p. 6
“we see a significant improvement as well, plus 3% in terms of percentage to net sales from 24% to 27%.”
Rachid Ayari, page 6 of the filed PDF · View the filing
Cash growth: 34%
p. 6
“So, we are growing by 34% in terms of cash, no major risk that we're facing.”
Rachid Ayari, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Diabetes business unit growth — double-digit growth above market
stated firmly by Deepak Arora
p. 3
“we will be investing ourselves into making sure that we optimize and maximize diabetes business unit, growing by double-digit and bring it above market growth”
Deepak Arora, page 3 of the filed PDF · View the filing
Partnership business growth reaching industry level — industry growth rate · 2027
stated conditionally by Rachid Ayari
p. 8
“maybe 2026, I don't I'm not expecting that we'll reach the industry growth. 2027, this is what we -- where we are evaluating right now.”
Rachid Ayari, page 8 of the filed PDF · View the filing
Dividend payout ratio — not lower than last year's payout
stated conditionally by Rachid Ayari
p. 10
“we are expecting that we will be minimum at last year payout, but then there are decisions and discussion that will be done at the Board and the final decision and the proposal will be from the Board”
Rachid Ayari, page 10 of the filed PDF · View the filing
Second half diabetes performance repeating first half — second half 2026
stated as an aspiration by Deepak Arora
p. 9
“that can be what I can assure you that we're not leaving any grounds to make sure that what we have seen in the first half to repeat it in second half.”
Deepak Arora, page 9 of the filed PDF · View the filing
Open market buyback
stated conditionally by Rachid Ayari
p. 13
“As today, all these proposals are discussed in the Board, so there are certain discussion, but as today, it's not in the strategy, let's say.”
Rachid Ayari, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management explained the slow growth was due to one-off safety stock build and sales return agreements in Q1 2025 that inflated the base, and said industry-level growth may not be reached until 2027.
Answered by Rachid Ayari
Asked by Rajkumar Vaidyanathan: Why is the partnership business showing prolonged slow growth and when will it catch up to industry growth?
p. 8
“maybe 2026, I don't I'm not expecting that we'll reach the industry growth. 2027, this is what we -- where we are evaluating right now.”
Rachid Ayari, page 8 of the filed PDF · View the filing
Management denied this, saying the partners have dedicated standalone teams for the Sanofi products.
Answered by Deepak Arora
Asked by Rajkumar Vaidyanathan: Are Emcure and Cipla pushing their own products and sidelining Sanofi products?
p. 9
“No, that can, we can tell you very clearly, as a partnership it's a win-win, and Emcure is really invested as we are invested, while the other products which they are bringing in have a separate team, but they have a team which is standalone team for Amaryl and also for the CV portfolio.”
Deepak Arora, page 9 of the filed PDF · View the filing
Management said cardiovascular and CNS partnerships remain part of strategy and expressed confidence in continued insulin portfolio momentum without committing to a specific growth number.
Answered by Deepak Arora
Asked by Rusmik Oza: Is the 14% diabetes growth sustainable, and is there any initiative beyond diabetes?
p. 9
“I don't know whether it's 14%, 15%, or 10%, but yes, the promise what we have with ourselves and to our patients and to our community is that we'll continue doing what we can do to support these patients in their progressive disease.”
Deepak Arora, page 9 of the filed PDF · View the filing
Management said diabetes remains the priority and they are evaluating innovative devices and platforms, with other products to be considered as the pipeline evolves.
Answered by Deepak Arora
Asked by Rusmik Oza: Are there identified products from the parent's pipeline that could be brought to India?
p. 10
“Currently we are evaluating whatever comes in the pipeline for diabetes, surely India will be a place to really focus upon. For this moment, whatever is available is the innovative devices, Bluetooth devices, AI platforms.”
Deepak Arora, page 10 of the filed PDF · View the filing
Management said patient profiles for once-weekly and once-daily insulins differ and they do not see a major shift, viewing the increased attention on insulins as beneficial overall.
Answered by Deepak Arora
Asked by Divyaxa Agnihotri: How does the entry of Novo Nordisk's Awiqli (once-weekly insulin) affect competitive intensity for Lantus, Toujeo and Soliqua?
p. 11
“We do not see a major shift which will happen, because the market is big.”
Deepak Arora, page 11 of the filed PDF · View the filing
Management said losses in Australia are being offset by growth in France, Italy, Turkey and Russia, and Goa is being positioned as a specialized manufacturing site, with tenders pending from South Africa.
Answered by Rachid Ayari
Asked by Kartik Bane: What is the strategy for the export business?
p. 12
“So, we succeed already for one product and still we've still waiting certain other action. We are expecting as well certain tenders from South Africa that we are waiting for the result.”
Rachid Ayari, page 12 of the filed PDF · View the filing
Management said the proposal has been discussed at the Board but is not currently part of the strategy.
Answered by Rachid Ayari
Asked by Yasser Lakdawala: Are there any plans to use cash for an open market share buyback?
p. 13
“As today, all these proposals are discussed in the Board, so there are certain discussion, but as today, it's not in the strategy, let's say.”
Rachid Ayari, page 13 of the filed PDF · View the filing
Risks flagged
Heavy competition in the Australian export market for mature products
p. 5
“And we are facing certain challenge from Australia market where, heavy competition in this market for the mature products”
Rachid Ayari, page 5 of the filed PDF · View the filing
One-off partnership transition impacts from prior year safety stock and sales return agreements distorting comparisons
p. 7
“There are other agreements, you know, with the partner related to sales returns that in the transition period, that was agreed. And this is, it was one-off, it was positive in Q1 2025.”
Rachid Ayari, page 7 of the filed PDF · View the filing
Aggressive competition in the CV/CNS generic partnership portfolio
p. 8
“But still, you know, the competition in the market is quite aggressive in this portfolio.”
Rachid Ayari, page 8 of the filed PDF · View the filing
Increased competitive intensity from new insulin entrants such as Novo Nordisk's once-weekly product
p. 11
“We are now being joined by Novo because basically everybody was focusing on GLP-1.”
Deepak Arora, page 11 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.